Idera Pharmaceuticals' Pending Acquisition

Idera Pharmaceuticals raised a round of funding on January 22, 2018. Investors include BioCryst Pharmaceuticals.

Idera Pharmaceuticals is a clinical stage biotechnology company with expertise in discovering, developing and commercializing novel nucleic acid therapeutics to treat patients with serious and life-th…

Articles about Idera Pharmaceuticals' Pending Acquisition: